SABER is developing an antimicrobial bandage to helping hospital staff reduce healthcare-associated infections.
SABER Corporation is developing an antimicrobial bandage to provide a cost saving solution by helping hospital staff reduce Healthcare-Associated Infections.SABER is developing a programmable antimicrobial bandage- a device utilizing blue light mainly in the wavelength range of 400-470nm (outside the range of UV light) for application on postoperative incisions and wound sites. It is designed to prevent bacterial contamination of the site, thus reducing the occurrence of SSIs. This antimicrobial light emitting bandage uses blue light’s proven abilities to inactivate a wide range of clinical pathogens regardless of their resistance to antibiotics, inactivate bacteria without developing resistance nor harming mammalian cells, to improve wound healing, and inactivate bacteria in the biofilm state [8-10]. The device is unique in its design and method of use because it is capable of automating disinfection, electronically sending performance information (providing improved accountability and real time information), is a thin transparent multilayer thermally managed LED sheet, and is a wearable device that does not interfere with standardized hospital infection prevention protocols. This device would be a paradigm shift in infection control and prevention because it brings antimicrobial blue light therapy into a compact wearable device that can be easily incorporated into infection prevention protocols.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 19, 2018 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |